

**Antitumor effect of afatinib, as a HER2-targeted therapy, in lung cancers harboring *HER2* oncogene alterations**

Ken Suzawa<sup>1</sup>, Shinichi Toyooka<sup>1,2,5</sup>, Masakiyo Sakaguchi<sup>3</sup>, Mizuki Morita<sup>4,5</sup>, Hiromasa Yamamoto<sup>1</sup>, Shuta Tomida<sup>5</sup>, Tomoaki Ohtsuka<sup>1</sup>, Mototsugu Watanabe<sup>1</sup>, Shinsuke Hashida<sup>1,2</sup>, Yuho Maki<sup>1</sup>, Junichi Soh<sup>1,5</sup>, Hiroaki Asano<sup>1</sup>, Kazunori Tsukuda<sup>1</sup>, Shinichiro Miyoshi<sup>1</sup>.

*Departments of <sup>1</sup>Thoracic, Breast and Endocrinological Surgery, <sup>2</sup>Clinical Genomic Medicine, <sup>3</sup>Cell Biology <sup>4</sup>Biorepository Research and Networking, and <sup>5</sup>Biobank, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558 Japan.*

**Address correspondence to:**

Shinichi Toyooka, M.D.

Department of Clinical Genomic Medicine, Okayama University Graduate School  
of Medicine, Dentistry and Pharmaceutical Sciences

2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

TEL: +81-86-235-7436, FAX: +81-86-235-7437

E-mail: toyooka@md.okayama-u.ac.jp

**Word count of the manuscript:** 3,533 words (including title page, excluding  
reference)

**Number of tables/figures:** 4 figures and 1 table

**Quantity of supporting information:** none

### Abstract

HER2 is a member of the HER family proteins containing four receptor tyrosine kinases and plays an important role in the pathogenesis of certain human cancers. In non-small cell lung cancer (NSCLC), *HER2* amplification or mutations have been reported. However, little is known about the benefit of HER2-targeted therapy for NSCLCs harboring *HER2* alterations. In this study, we investigated the anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring *HER2* oncogene alterations, including novel *HER2* mutations in transmembrane domain, which we recently identified. Normal bronchial epithelial cells, BEAS-2B, ectopically overexpressing wild-type HER2 or mutants (A775insYVMA, G776VC, G776LC, P780insGSP, V659E, and G660D) showed constitutive autophosphorylation of HER2 and activation of downstream signaling. They were sensitive to afatinib, but insensitive to gefitinib. Furthermore, we examined the antitumor activity of afatinib and gefitinib in several NSCLC cell lines, and investigated the association between their genetic alterations and sensitivity to afatinib treatment. In *HER2*-altered NSCLC cells (H2170, Calu-3, and H1781), afatinib down-regulated the phosphorylation of HER2 and EGFR as well as their downstream signaling, and induced an antiproliferative effect through

G1 arrest and apoptotic cell death. In contrast, *HER2*- or *EGFR*-non-dependent NSCLC cells were insensitive to afatinib. In addition, these effects were confirmed *in vivo* by using a xenograft mouse model of *HER2*-altered lung cancer cells. Our results suggest that afatinib is a therapeutic option as a *HER2*-targeted therapy for NSCLC harboring *HER2*-amplification or mutations. (235 words)

**Key words:** non-small cell lung cancer, *HER2*, *ERBB2*, *HER2*-targeted therapy, afatinib

**Abbreviations:** *HER2*, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer; *EGFR*, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; *ALK*, anaplastic lymphoma kinase

## Introduction

Lung cancer remains the leading cause of cancer-related death worldwide.<sup>(1)</sup> Recent developments in the genomic characterization of tumors have contributed to novel therapeutic approaches, and some molecular-targeted therapies based on the genetic profiles of tumors have improved patient survival. For example, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib or erlotinib, have shown marked antitumor activity in non-small cell lung cancer (NSCLC) patients with an activating *EGFR* mutations, and crizotinib, an anaplastic lymphoma kinase (ALK) TKI, has shown similar promise for NSCLC patients with *ALK* gene rearrangements.<sup>(2, 3)</sup> Furthermore, other oncogenic alterations, such as *KRAS*, *NRAS*, *BRAF*, *MET*, and *FGFR*, have been identified in some subsets of NSCLC.<sup>(4, 5)</sup>

Human epidermal growth factor 2 (HER2, also known as ERBB2) is a member of the HER family containing four receptor tyrosine kinases. This receptor is frequently overexpressed in various human cancers, and many preclinical studies have shown that overexpression of HER2 or mutations of the *HER2* kinase domain play an important role in oncogenic transformation and tumorigenesis.<sup>(6-9)</sup> In NSCLC patients, HER2 overexpression and *HER2*

amplification were reported in 11% to 32% and in 2% to 23%, respectively.<sup>(10-13)</sup> *HER2* mutations were identified in approximately 2% to 4% of NSCLCs and were usually mutually exclusive with other driver mutations.<sup>(14, 15)</sup> Shigematsu et al. reported that all *HER2* mutations in tyrosine kinase domain were located in a same loop of exon 20, consisting of A775insYVMA (55%), G776VC (18%), P780insGSP (18%), and G776LC (9%).<sup>(15)</sup> Recently, we have identified two novel mutations in the transmembrane domain of *HER2* encoded by exon 17 (V659E and G660D) in lung adenocarcinomas. Our preliminary data suggested that these mutations might be oncogenic alterations of lung adenocarcinoma.<sup>(16)</sup> However, little is known about the benefit of HER2-targeted therapy for NSCLCs harboring *HER2* alterations.

Afatinib, also known as BIBW2992, is an irreversible inhibitor of EGFR and HER2, and has recently been approved for the treatment of *EGFR*-mutant NSCLCs in several countries. In two randomized phase III trials, afatinib showed significant benefit in progression-free survival compared with standard doublet chemotherapy in NSCLC patients with *EGFR* mutations.<sup>(17, 18)</sup>

In this study, we investigated the efficacy of afatinib as a HER2-targeted therapy *in vitro* in NSCLC cells harboring *HER2* gene amplification or mutations,

including novel mutations in transmembrane domain, and confirmed these antitumor effects *in vivo* via a xenograft mouse model of *HER2*-altered lung cancer cells.

## Materials and Methods

### Cell lines and reagents

Eight lung cancer cell lines (A549, Calu-3, HCC827, NCI-H1299, NCI-H1781, NCI-H1975, NCI-H1993, and NCI-H2170), two breast cancer cell lines (SK-BR-3 and BT-474), and one normal human bronchial epithelial cell line (BEAS-2B) were used in this study. These cell lines, except A549, SK-BR-3, BT-474 and BEAS-2B, were kindly provided by Dr. Adi F. Gazdar (The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA), who established these lines with Dr. John D. Minna.<sup>(19, 20)</sup> A549, SK-BR-3 and BT-474 were purchased from American Type Culture Collection (Manassas, VA). BEAS-2B was purchased from European Collection of Cell Cultures (Porton Down, UK). All lung cancer cells were cultured in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS) and the other cells were maintained in DMEM with 10% FBS. They were grown in a humidified incubator with 5% CO<sub>2</sub> at 37°C. Afatinib and

gefitinib were purchased from Sykkinase Pty Ltd. (San Diego, CA, USA) and InvivoGen (San Diego, CA), respectively.

### **Plasmid constructs and transfection**

Human cDNAs encoding full-length *HER2* (wild-type and its variants A775insYVMA, G776VC, G776LC, P780insGSP, V659E, and G660D) were inserted into the pIDT-SMART (C-TSC) vector, pCMViR-TSC<sup>(21)</sup>, respectively. Transient transfection of the BEAS-2B cells with the mammalian expression vectors was performed using Lipofectamine 3000 (Life Technologies, Carlsbad, CA) according to the manufacturer's protocol.

### **Three-dimensional structure analysis**

A three-dimensional structure model of HER2-afatinib was made by copying afatinib coordinates to the substrate binding pocket of a HER2 kinase domain structure (PDB ID: 3RCD) from a superimposed EGFR-afatinib complex structure (PDB ID: 4G5J). The HER2 mutation sites of exon 20 reported in previous papers were mapped on the modeled complex structure. The figure was prepared using PyMOL (Schrödinger, New York, NY).

Secondary structure assignment for the HER2 kinase domain structure was performed with STRIDE to determine the residue numbers of beginning and

end of the  $\alpha$ C- $\beta$ 4 loop of HER2 kinase domain. <sup>(22)</sup>

### **Western blot analysis**

The total cell lysate was extracted with lysis buffer, a mixture of RIPA buffer, phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich, St. Louis, MO), and Complete Mini (Roche, Basel, Switzerland). Western blot analysis was performed by conventional methods using the following primary antibodies: anti-EGFR, phospho-EGFR (Tyr1068), HER2, phospho-HER2 (Tyr1221/1222), Akt, phospho-Akt (Ser473), p44/p42 mitogen-activated protein kinase (MAPK), phospho-p44/p42 MAPK, cleaved PARP (Asp214) (Cell Signaling Technology, Danvers, MA), and  $\beta$ -actin (used as loading control, Merck Millipore, Billerica, MA). The secondary antibody was horseradish-peroxidase (HRP)-conjugated anti-mouse or anti-rabbit IgG (Santa Cruz Biotechnology, Dallas, TX). To detect specific signals, the membranes were examined using the ECL Prime Western Blotting Detection System (GE Healthcare, Amersham, UK) and LAS-3000 (Fujifilm, Tokyo, Japan).

### **DNA extraction**

Genomic DNA was obtained from the cell lines with a DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions.

### **Copy number analysis by real-time PCR**

Copy number gains of *EGFR* and *HER2* were measured by real-time quantitative PCR (qPCR) with the SYBR Green Method, using Power SYBR Green PCR Master Mix (Life Technologies), as previously reported.<sup>(23)</sup> In brief, *LINE-1* was used as a reference gene for each copy number analysis. The dosage of each target and reference gene was calculated by the standard curve method. Relative copy number of each sample was determined by comparing the ratio of the target gene to *LINE-1* in each sample with the ratio of these genes in standard genomic DNA (Merck KGaA, Darmstadt, Germany).

### **Cell growth inhibition assay**

Cells were cultured with or without drugs for 72 hours and the sensitivities to the drugs were determined using a modified MTS assay with CellTiter 96 Aqueous One Solution Reagent (Promega, Fitchburg, WI), as previously described.<sup>(24)</sup> The antiproliferative activities of each drug are shown as IC<sub>50</sub>, which is the concentration of the drug required to inhibit cell proliferation by 50%.

### **Cell cycle analysis**

The effects of afatinib on the cell cycle distribution were assessed using

a propidium iodide staining-based assay with the CycleTEST PLUS DNA Reagent Kit and FACSCaliber (Becton Dickinson, Franklin Lakes, NJ). Untreated cells and cells treated with 0.1  $\mu\text{M}$  afatinib for 24 or 48 hours were subjected to cell cycle analysis. Doublets, cell debris, and fixation artifacts were gated out, and cell cycle analysis was performed with CellQuest, version 3.1.

### **Xenograft model**

Six-week-old nonobese diabetic/severe combined immunodeficient (NOD/SCID) female mice were purchased from Charles River Laboratories (Yokohama, Japan). All mice were provided with sterilized food and water, and housed in a barrier facility under a 12-hour light/12-hour dark cycle. Each cell line ( $5 \times 10^6$ ) was suspended with 200  $\mu\text{l}$  RPMI 1640 media with Matrigel Basement Membrane Matrix (Corning, Corning, NY) and subcutaneously injected into the backs of the mice. The tumor volume was calculated using the empirical formula  $V = 1/2 \times [(\text{the shortest diameter})^2 \times (\text{the longest diameter})]$ . When the tumors exceeded approximately 50  $\text{mm}^3$ , mice were randomly allocated to two groups that received either vehicle or 20 mg/kg afatinib. Afatinib was prepared in 0.5 w/v (%) methyl cellulose. Vehicles and afatinib were administered orally as a suspension by gavage once daily, six days per week. Tumor volume was

measured three times a week with calipers. After 4 weeks of treatment, the mice were sacrificed and the tumors were harvested and photographed.

### **Statistical analysis**

Statistical analysis was performed with GraphPad Prism, version 6.0.3, J (GraphPad Software, San Diego, CA). Group differences were compared using one-way ANOVA followed by Dunnett's test or two-way ANOVA for repeated measurements.  $P < 0.05$  was considered statistically significant.

## **Results**

### ***HER2* alteration activates *HER2* signaling, which is inhibited by afatinib**

To examine the effect of *HER2* alterations on signal transduction pathways, normal bronchial epithelial cells (BEAS-2B) were transiently transfected with wild-type or six mutant *HER2*-containing vectors, consisting of four kinase domain mutations (A775insYVMA, G776VC, G776LC, and P780insGSP) and two transmembrane domain mutations (V659E and G660D), which were reported in NSCLCs. <sup>(15, 16)</sup> Cells expressing wild-type and all six *HER2* mutants showed strong constitutive autophosphorylation of *HER2* in the absence of serum, and stronger phosphorylation of EGFR, which is assumed to

be one of HER2 dimerization partners, and AKT compared with the vector control. Furthermore, all cells expressing *HER2*-mutants showed increased phosphorylation of HER2, EGFR, and AKT compared with those expressing wild-type (Fig. 1A).

Next, we assessed the affinity changes of afatinib to HER2 kinase domain caused by major *HER2* mutations in exon 20. We modeled the three-dimensional structure of HER2-afatinib complex and marked the location of major *HER2* mutations, which are reported in the previous paper <sup>(15)</sup> (Fig.1B). Mutations of exon 20 were concentrated in the exposed area on the protein surface (from A775 to P780) of the  $\alpha$ C- $\beta$ 4 loop (from M774 to R784) of the HER2 kinase domain, and this area was located on the back side of the ATP-binding pocket as shown in its modeled complex structure. This structural feature suggests that the major *HER2* mutations in exon 20 could not directly inhibit the binding of ATP and afatinib to the HER2 kinase domain.

We then examined the sensitivity of BEAS-2B cells ectopically expressing wild-type or mutant *HER2* to the EGFR-TKI (gefitinib) and EGFR/HER2-TKI (afatinib). Forty-eight hours after transfection, cells were treated with or without gefitinib or afatinib for six hours. We then analyzed the HER2 signaling pathway

via western blotting. Although gefitinib showed little effect on the phosphorylation of HER2 and EGFR, treatment with afatinib inhibited phosphorylation of HER2, EGFR, and AKT (Fig. 1C). These results indicate that afatinib was more effective than gefitinib in inhibiting HER2-driven signals.

### **Afatinib inhibits growth of both *HER2*-amplified and *HER2*-mutant lung cancer cells**

We examined the antitumor activity of afatinib and gefitinib in several NSCLC cell lines, and investigated the association between their genetic alterations and sensitivity to afatinib treatment (Table 1 and Fig. 2A). The cell lines of this panel were selected on the basis of previously published genotyping reports<sup>(19, 25)</sup> and consisted of 2 *HER2*-amplified (NCI-H2170 and Calu-3), 1 *HER2*-mutant (NCI-H1781), 2 *EGFR*-mutant (NCI-H1975 and HCC827), 1 *KRAS*-mutant (A549), 1 *NRAS*-mutant (NCI-H1299), and 1 *MET*-amplified (NCI-H1993) NSCLC cell lines; two *HER2*-amplified breast cancer cell lines (SK-BR-3 and BT-474) were also analyzed. We determined the copy number gains of *EGFR* and *HER2* using real-time PCR, and sensitivity was assessed, with the IC<sub>50</sub> values for each cell line calculated using an MTS assay. Two NSCLC cell lines,

H2170 and Calu-3, and two breast cancer cell lines, SK-BR-3 and BT-474, showed high *HER2*-amplification, with copy number values of 94.6, 110.9, 23.0, and 32.0, respectively. In contrast, copy number values of *HER2* in H1781 cells (*HER2*-mutant cells) or the other cell lines in this panel did not exceed approximately 3. Next, for drug sensitivity, the proliferation of two *HER2*-amplified lung cancer cell lines, H2170 and Calu-3, was inhibited by afatinib, with  $IC_{50}$  values of 0.140 and 0.086  $\mu\text{M}$ , respectively. Afatinib also exhibited strong antiproliferative effects on H1781 cells, with an  $IC_{50}$  of 0.039  $\mu\text{M}$ . Regarding the sensitivity to gefitinib among *HER2*-altered cells, H2170 and H1781 cells, were resistant to gefitinib ( $IC_{50} > 3 \mu\text{M}$ ). On the other hand, Calu-3 cells were partially sensitive to gefitinib, with an  $IC_{50}$  of 0.471  $\mu\text{M}$ , which was consistent with a previous report.<sup>(26)</sup> Furthermore, HCC827 cells (*EGFR*-mutant) were sensitive to afatinib with  $IC_{50}$  values of 0.001, and H1975 cells (*EGFR*-L858R/T790M mutant) were moderately resistant to afatinib with  $IC_{50}$  values of 0.713  $\mu\text{M}$ . *HER2*- or *EGFR*-non-dependent NSCLC cells A549 (*KRAS*-mutant cells), H1299 (*NRAS*-mutant cells), and H1993 (*MET*-amplified cells), were insensitive ( $IC_{50} > 2 \mu\text{M}$ ). In addition, afatinib showed antiproliferative effects on *HER2*-amplified breast cancer cell lines (SK-BR-3 and BT-474 cells), with an  $IC_{50}$  of 0.002  $\mu\text{M}$  for each

cell.

Next, we assessed the effect of afatinib on signal transduction pathways in *HER2*-amplified or *HER2*-mutant lung cancer cells. After six hours of treatment with afatinib, cells were lysed followed by western blot analysis. As shown in Fig. 2B, afatinib potently inhibited phosphorylation of both *HER2* and *EGFR* at a concentration of 0.1  $\mu$ M, and the downstream signals, phosphorylation of *AKT* and *MAPK*, were also inhibited in both *HER2*-amplified and *HER2*-mutant lung cancer cells. Taken together, these results suggest that afatinib showed strong antitumor activity in both *HER2*-amplified and *HER2*-mutant lung cancer cells *in vitro*.

### **Afatinib induces cell-cycle arrest and apoptosis in *HER2*-dependent cells**

To assess the mechanism of growth inhibition, we then examined the effect of afatinib on cell cycle and apoptosis in *HER2*-amplified (H2170 and Calu-3 cells), *HER2*-mutant (H1781 cells), and *HER2*- or *EGFR*-non-dependent lung cancer cells (A549 cells). Cells were treated with 0.1  $\mu$ M afatinib for 24 or 48 hours, and analyzed by flow cytometry. To analyze cell cycle distribution, the sub-G1 fraction was excluded and the percentages of each phase were measured

(Fig. 3A). Treatment with afatinib caused an increase in the number of H2170, Calu-3, and H1781 cells occupying the G1 phase relative to untreated cells, whereas G1 arrest was not detected in A549 cells. Next, we investigated the ability of afatinib to induce apoptosis. Cell apoptosis was analyzed with cleaved PARP antibody, as an apoptosis marker, by western blotting. Afatinib (0.1  $\mu$ M) induced apoptosis in a time-dependent manner in H2170, Calu-3, and H1781 cells; however, A549 cells did not express cleaved PARP with the treatment (Fig. 3B). These results showed that afatinib induced antiproliferative effects through G1 arrest and apoptotic cell death in *HER2*-altered cells (H2170, Calu-3, and H1781 cells), whereas *HER2*- or *EGFR*-non-dependent NSCLC cells were insensitive to afatinib.

### **Antitumor effect of afatinib on a xenograft mouse model of *HER2*-altered cells**

On the basis of our *in vitro* data, we investigated the antitumor effect of afatinib in a xenograft mouse model of *HER2*-driven lung cancer. H2170 cells (*HER2*-amplified cells) and H1781 cells (*HER2*-mutant cells) were used in this experiment. The dose of afatinib was chosen on the basis of previous reports.<sup>(9)</sup>

<sup>27)</sup> One week after transplantation, when tumors exceeded approximately 50 mm<sup>3</sup>, we started to orally administer vehicle alone or afatinib at 20 mg/kg for six days per week. As shown in Fig. 4A, B, C, and D, afatinib treatment significantly inhibited the tumor growth of both H2170 and H1781 xenografts compared with the vehicle control ( $P < 0.0001$  by repeated measurements of ANOVA).

## Discussion

HER2 is frequently overexpressed in various human cancers, and targeted therapies for HER2-positive tumors have been proven clinically effective in breast and gastric cancers.<sup>(28, 29)</sup> However, it is still unclear whether HER2-targeted therapy shows clinical benefit in NSCLC patients with *HER2* aberrations. Previous clinical trials failed to show a clinical benefit with trastuzumab monotherapy or an additional effect of trastuzumab to conventional first-line chemotherapy in HER2-positive NSCLC patients by immunohistochemistry (IHC) analysis.<sup>(30-32)</sup> On the other hand, a subgroup of patients with high HER2 expression (IHC 3+), *HER2* gene amplification, or *HER2* mutations were observed to have a good response to HER2-targeted treatment.<sup>(30, 33, 34)</sup> Patient selection based on molecular profiles of tumor cells is important for achieving the

maximum benefit of the targeted therapy, because preferable responses can be diluted easily without optimal patient selection. Therefore, to determine the optimal patient selection for *HER2*-driven NSCLCs, further clinical and preclinical investigations are required.

In previous preclinical studies, Perera et al. reported the efficacy of afatinib and the combination of afatinib with mTOR inhibitor rapamycin in *HER2*-mutant A775insYVMA transgenic mice or H1781 xenografts.<sup>(9)</sup> As for other EGFR/*HER2*-TKIs, neratinib (HKI-272) or dacomitinib (PF00299804) showed efficacy in lung cancer cells with *HER2* amplification or mutation *in vitro*.<sup>(35-37)</sup> In this study, we showed that afatinib efficiently inhibited growth of both *HER2*-amplified and *HER2*-mutant lung cancer cells as well as that of *EGFR*-mutant lung cancer cells at clinically achievable concentration <sup>(38)</sup> via G1 arrest and apoptotic cell death. In addition, we showed afatinib inhibited *HER2* phosphorylation in *HER2*-mutant cells in the transmembrane domain. These facts were confirmed in BEAS-2B cells with various *HER2* mutants transfection. While the rate of *HER2* mutations in the transmembrane domain is rare, afatinib may be a therapeutic option in patients with this alteration.

Regarding the *HER2* mutations in lung cancer, reported mutations are

concentrated in exon 20 and the majority of these mutations are A775insYVMA, G776VC, G776LC, and P780insGSP except one mutation L755S in exon 19<sup>(15, 39)</sup> and two transmembrane domain mutations V659E and G660D in exon 17.<sup>(16)</sup> According to COSMIC database (<http://cancer.sanger.ac.uk/cosmic>), A775insYVMA, G776VC, G776LC, and P780insGSP mutations account for 74% of all *HER2* mutations in lung cancers. In addition, mutations in the  $\alpha$ C- $\beta$ 4 loop (M774-R784) of the *HER2* kinase domain account for 81% of *HER2* mutations at the time of our survey on October 12, 2015. As mentioned, the three-dimensional structure of the modeled *HER2*-afatinib complex shows that the major mutations of *HER2* are concentrated in the exposed area (A775-P780) of the  $\alpha$ C- $\beta$ 4 loop, which is located on the back side of the ATP-binding pocket. Thus, these mutations are considered not to directly inhibit the binding of afatinib to *HER2* kinase domain. These facts with our experimental results support that afatinib is effective for majority of *HER2* mutations.

Though *EGFR*-mutant NSCLCs initially respond to the antitumor effects of *EGFR*-TKIs, most of these tumors eventually acquire resistance to the treatment. Several mechanisms of resistance have been reported, and secondary T790M mutation in exon 20 of *EGFR* is the most common one.<sup>(40, 41)</sup>

In addition, Takezawa et al. recently reported *HER2* amplification as a novel mechanism of acquired resistance to reversible EGFR-TKIs in patients with NSCLCs harboring *EGFR*-mutations.<sup>(42)</sup> Considering the findings we obtained, afatinib may be useful for overcoming reversible EGFR-TKI resistance acquired via *HER2* amplification.

In conclusion, we demonstrated the antitumor effect of afatinib in lung cancers harboring *HER2* alterations. Our results suggest that afatinib is a therapeutic option as a *HER2*-targeted therapy for NSCLC harboring *HER2*-amplification or mutations.

### **Acknowledgments**

We thank Ms. Fumiko Isobe (Department of Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan) for her technical assistance. This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science [JSPS KAKENHI Grant number: 25293302 (to ST) and 26293318 (to SM)].

**Disclosure Statement**

No potential conflicts of interest were disclosed.

## References

- 1 Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. *J Thorac Oncol.* 2008; 3: 819-31.
- 2 Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med.* 2009; 361: 947-57.
- 3 Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med.* 2010; 363: 1693-703.
- 4 Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA.* 2014; 311: 1998-2006.
- 5 Pao W, Girard N. New driver mutations in non-small-cell lung cancer. *Lancet Oncol.* 2011; 12: 175-80.
- 6 Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. *Oncogene.* 1992; 7: 1859-66.
- 7 Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in

- transformation. *Ann Oncol.* 2001; 12 Suppl 1: S9-13.
- 8 Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. *Cancer Cell.* 2006; 10: 25-38.
- 9 Perera SA, Li D, Shimamura T, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. *Proc Natl Acad Sci U S A.* 2009; 106: 474-9.
- 10 Tan D, Deeb G, Wang J, et al. HER-2/neu protein expression and gene alteration in stage I-IIIa non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. *Diagn Mol Pathol.* 2003; 12: 201-11.
- 11 Pellegrini C, Falleni M, Marchetti A, et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. *Clin Cancer Res.* 2003; 9: 3645-52.

- 12 Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. *J Clin Oncol.* 2005; 23: 5007-18.
- 13 Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer. *Clin Cancer Res.* 2006; 12: 4377s-83s.
- 14 Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. *Nature.* 2004; 431: 525-6.
- 15 Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. *Cancer Res.* 2005; 65: 1642-6.
- 16 Yamamoto H, Higasa K, Sakaguchi M, et al. Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas. *J Natl Cancer Inst.* 2014; 106: djt338.
- 17 Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol.* 2013; 31: 3327-34.
- 18 Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for

- first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *Lancet Oncol.* 2014; 15: 213-22.
- 19 Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. *PLoS One.* 2009; 4: e4576.
- 20 Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. *Cancer Res.* 2000; 60: 4894-906.
- 21 Sakaguchi M, Watanabe M, Kinoshita R, et al. Dramatic increase in expression of a transgene by insertion of promoters downstream of the cargo gene. *Mol Biotechnol.* 2014; 56: 621-30.
- 22 Frishman D, Argos P. Knowledge-based protein secondary structure assignment. *Proteins.* 1995; 23: 566-79.
- 23 Soh J, Okumura N, Lockwood WW, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. *PLoS One.* 2009; 4: e7464.

- 24 Shien K, Toyooka S, Yamamoto H, et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. *Cancer Res.* 2013; 73: 3051-61.
- 25 Kubo T, Yamamoto H, Lockwood WW, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. *Int J Cancer.* 2009; 124: 1778-84.
- 26 Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. *Proc Natl Acad Sci U S A.* 2005; 102: 3788-93.
- 27 Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. *Oncogene.* 2008; 27: 4702-11.
- 28 Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med.* 2001; 344: 783-92.
- 29 Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer

- (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet*. 2010; 376: 687-97.
- 30 Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. *Ann Oncol*. 2004; 15: 19-27.
- 31 Lara PN, Jr., Laptalo L, Longmate J, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. *Clin Lung Cancer*. 2004; 5: 231-6.
- 32 Clamon G, Herndon J, Kern J, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. *Cancer*. 2005; 103: 1670-5.
- 33 De Greve J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. *Lung Cancer*. 2012; 76: 123-7.
- 34 Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. *J*

- Clin Oncol. 2013; 31: 1997-2003.
- 35 Shimamura T, Ji H, Minami Y, et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV\_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. *Cancer Res.* 2006; 66: 6487-91.
- 36 Minami Y, Shimamura T, Shah K, et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. *Oncogene.* 2007; 26: 5023-7.
- 37 Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. *Cancer Res.* 2007; 67: 11924-32.<sup>(1)</sup>
- 38 Murakami H, Tamura T, Takahashi T, et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). *Cancer Chemother Pharmacol.* 2012; 69: 891-9.
- 39 Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase

mutations in lung adenocarcinomas. *Clin Cancer Res.* 2012; 18: 4910-8.

40 Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med.* 2005; 352: 786-92.

41 Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. *Clin Cancer Res.* 2006; 12: 6494-501.

42 Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation. *Cancer Discov.* 2012; 2: 922-33.

### Figure Legends

**Figure 1.** Overexpressing wild-type or mutant *HER2* activates *HER2* signaling, and afatinib inhibits them. (A) BEAS-2B cells were transiently transfected with wild-type *HER2*, its variants, A775insYVMA, G776VC, G776LC, P780insGSP, G660D, and V659E, or vector control. Approximately 36 hours after the

transfection, cells were serum-starved overnight. Lysates were subjected to western blot analysis with the indicated antibodies. (B) Location of the major mutation site and the ATP-binding pocket of the HER2 kinase domain in the modeled HER2-afatinib complex structure. The afatinib is shown as stick. Residues at the mutation site of the HER2 kinase domains (A775, G776, and P780) are shown as sphere. These residues are concentrated in an exposed area on the protein surface (A775-P780) of the  $\alpha$ C- $\beta$ 4 loop (M774-R784), which is located on the back side of the ATP-binding pocket. (C) Forty-eight hours after the transfection, cells were treated with or without 1.0  $\mu$ M gefitinib or 0.1  $\mu$ M afatinib for six hours. Lysates were subjected to western blot analysis with the indicated antibodies.

**Figure 2.** Afatinib inhibits both *HER2*-amplified and *HER2*-mutant NSCLC and breast cancer cells. (A) *HER2*-amplified and *HER2*-mutant NSCLC cells were treated with afatinib or gefitinib for 72 hours and  $IC_{50}$  values were determined using a MTS assay. Error bars indicate standard deviations. (B) Cells were treated with the indicated concentrations of afatinib for six hours and lysates were subjected to western blot analysis with the indicated antibodies.



**Figure 3.** Afatinib induces cell-cycle arrest and apoptosis in *HER2*-dependent

lung cancer cells. (A) NSCLC cells were treated with 0.1  $\mu\text{M}$  afatinib for 24 or 48 hours and subjected to cell cycle analysis using flow cytometry. The graph represents the mean percentages of each phase in live cells  $\pm$  SD of triplicate cultures. \*  $P < 0.05$  compared with vehicle controls by one-way ANOVA followed by Dunnett's test. (B) Lysates from NSCLC cells were collected at the indicated time points after the addition of 0.1  $\mu\text{M}$  afatinib and subjected to western blot analysis with the indicated antibodies.

**Figure 4.** Afatinib shows a strong antitumor effect on tumor growth in xenograft mouse model of *HER2*-altered lung cancer cells. (A) Mice with H2170 tumors were given vehicle or afatinib. Tumor volume was determined at the indicated days after the onset of treatment. Data represent mean  $\pm$  SE ( $n = 8$ ). \*  $P < 0.05$  compared with vehicle controls by two-way ANOVA for repeated measurements. (B) Appearance of H2170 tumors at the time of sacrifice after treatment. (C) Mice with H1781 tumors were given vehicle or afatinib and analyzed as in (A). Data represent mean  $\pm$  SE ( $n = 8$ ). \*  $P < 0.05$  compared with vehicle controls by two-way ANOVA for repeated measurements. (D) Appearance of H1781 tumors at the time of sacrifice after treatment.





**A****B**




**A****B****C****D**

Table 1  
 Characteristics and IC<sub>50</sub> values for afatinib and gefitinib of NSCLC and breast cancer cell lines

Histologic Type	Cell Line	Histologic subtype	Gene copy number		Mutation status		Genetic alteration	IC <sub>50</sub> (μM)	
			<i>EGFR</i>	<i>HER2</i>	<i>EGFR</i>	<i>HER2</i>		afatinib	gefitinib
NSCLC	H2170	SQ	2.0	94.6	WT	WT	<i>HER2</i> amplification	0.140	3.114
	Calu-3	AD	4.0	110.9	WT	WT	<i>HER2</i> amplification	0.086	0.471
	H1781	AD	2.1	2.6	WT	G776VC	<i>HER2</i> mutation	0.039	3.565
	HCC827	AD	48.7	2.3	Exon 19 del(E746-A750)		<i>EGFR</i> mutation	0.001	0.045
	H1975	AD	3.9	2.5	L858R, T790M		<i>EGFR</i> mutation	0.713	> 10
	A549	AD	2.8	3.1	WT	WT	<i>K-ras</i> mutation	5.275	> 10
	H1299	LC	2.1	1.5	WT	WT	<i>N-ras</i> mutation	4.667	> 10
	H1993	AD	2.9	1.8	WT	WT	<i>MET</i> amplification	2.309	> 10
Breast cancer	SKBR3	AD	2.7	23.0	WT	WT	<i>HER2</i> amplification	0.002	1.207
	BT474	AD	2.9	32.0	WT	WT	<i>HER2</i> amplification	0.002	0.251

Abbreviations: IC<sub>50</sub>, half maximal inhibitory concentration; NSCLC, non-small cell lung cancer; SQ, squamous cell carcinoma; AD, adenocarcinoma; LC, large cell carcinoma; WT, wild-type